PDF(Pubmed)
Abstract：
BACKGROUND: Obesity is a chronic inflammatory disorder that increases the risk of cardiovascular diseases (CVDs). Given the high CVD mortality rate among individuals with obesity, early screening should be considered. Plasminogen activator inhibitor (PAI-1), a cytokine that links obesity and CVDs, represents a promising biomarker. However, PAI-1 is not part of the clinical routine due to its high cost. Therefore, it is necessary to find good predictors that would allow an indirect assessment of PAI-1.
METHODS: This study enrolled 47 women with severe obesity (SO). The obtained anthropometric measurements included weight, height, neck (NC), waist (WC), and hip circumference (HC). Blood samples were collected to analyse glucose and lipid profiles, C-reactive protein, liver markers, adiponectin, and PAI-1 (determined by ELISA immunoassay). Homeostasis model assessment-adiponectin (HOMA-AD), homeostasis model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), triglyceride-glucose index (TyG), and atherogenic index of plasma (AIP) were calculated. The women were grouped according to PAI-1 levels. The data were analysed using IBM SPSS Statistics, version 21. The significance level for the analysis was set at 5%.
RESULTS: Women with SO who have higher levels of PAI-1 have lower values of high-density lipoprotein cholesterol (HDL) (p = 0.037) and QUICKI (0.020) and higher values of HOMA-AD (0.046) and HOMA-IR (0.037). HOMA-IR was demonstrated to be a good predictor of PAI-1 in this sample (B = 0.2791; p = 0.017).
CONCLUSIONS: HOMA-IR could be used as a predictor of PAI-1 levels, pointing out the relevance of assessing glycaemic parameters for the prevention of CVDs in women with SO.
METHODS: This study enrolled 47 women with severe obesity (SO). The obtained anthropometric measurements included weight, height, neck (NC), waist (WC), and hip circumference (HC). Blood samples were collected to analyse glucose and lipid profiles, C-reactive protein, liver markers, adiponectin, and PAI-1 (determined by ELISA immunoassay). Homeostasis model assessment-adiponectin (HOMA-AD), homeostasis model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), triglyceride-glucose index (TyG), and atherogenic index of plasma (AIP) were calculated. The women were grouped according to PAI-1 levels. The data were analysed using IBM SPSS Statistics, version 21. The significance level for the analysis was set at 5%.
RESULTS: Women with SO who have higher levels of PAI-1 have lower values of high-density lipoprotein cholesterol (HDL) (p = 0.037) and QUICKI (0.020) and higher values of HOMA-AD (0.046) and HOMA-IR (0.037). HOMA-IR was demonstrated to be a good predictor of PAI-1 in this sample (B = 0.2791; p = 0.017).
CONCLUSIONS: HOMA-IR could be used as a predictor of PAI-1 levels, pointing out the relevance of assessing glycaemic parameters for the prevention of CVDs in women with SO.
摘要：
背景：肥胖是一种慢性炎症性疾病，会增加心血管疾病（CVDs）的风险。鉴于肥胖个体的心血管疾病死亡率较高，应考虑早期筛查。纤溶酶原激活剂抑制剂（PAI-1），一种连接肥胖和心血管疾病的细胞因子，代表了一个有希望的生物标志物。然而,PAI-1由于其高成本而不是临床常规的一部分。因此,有必要找到可以间接评估PAI-1的良好预测因子。
方法：本研究纳入了47名重度肥胖（SO）女性。获得的人体测量包括体重，高度,颈部(NC),腰部(WC),和臀围（HC）。收集血液样本以分析葡萄糖和脂质分布，C反应蛋白,肝脏标志物,脂联素,和PAI-1(通过ELISA免疫测定测定)。稳态模型评估-脂联素（HOMA-AD），胰岛素抵抗的稳态模型评估（HOMA-IR），定量胰岛素敏感性检查指数（QUICKI），甘油三酯-葡萄糖指数（TyG），计算血浆致动脉粥样硬化指数(AIP)。根据PAI-1水平对妇女进行分组。使用IBMSPSSStatistics分析数据，版本21.分析的显著性水平设定为5%。
结果：具有较高水平PAI-1的SO女性的高密度脂蛋白胆固醇（HDL）（p=0.037）和QUICKI（0.020）的值较低，而HOMA-AD（0.046）和HOMA-IR（0.037）的值较高。HOMA-IR被证明是该样品中PAI-1的良好预测因子(B=0.2791;p=0.017)。
结论：HOMA-IR可作为PAI-1水平的预测因子，指出评估血糖参数与预防女性SO患者心血管疾病的相关性。
方法：本研究纳入了47名重度肥胖（SO）女性。获得的人体测量包括体重，高度,颈部(NC),腰部(WC),和臀围（HC）。收集血液样本以分析葡萄糖和脂质分布，C反应蛋白,肝脏标志物,脂联素,和PAI-1(通过ELISA免疫测定测定)。稳态模型评估-脂联素（HOMA-AD），胰岛素抵抗的稳态模型评估（HOMA-IR），定量胰岛素敏感性检查指数（QUICKI），甘油三酯-葡萄糖指数（TyG），计算血浆致动脉粥样硬化指数(AIP)。根据PAI-1水平对妇女进行分组。使用IBMSPSSStatistics分析数据，版本21.分析的显著性水平设定为5%。
结果：具有较高水平PAI-1的SO女性的高密度脂蛋白胆固醇（HDL）（p=0.037）和QUICKI（0.020）的值较低，而HOMA-AD（0.046）和HOMA-IR（0.037）的值较高。HOMA-IR被证明是该样品中PAI-1的良好预测因子(B=0.2791;p=0.017)。
结论：HOMA-IR可作为PAI-1水平的预测因子，指出评估血糖参数与预防女性SO患者心血管疾病的相关性。
